Spots Global Cancer Trial Database for Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Official Title: An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Study ID: NCT01466036

Conditions

Carcinoid Tumor

Pancreatic Neuroendocrine Tumor

Interventions

Cabozantinib

Study Description

Brief Summary: Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

Detailed Description: Subjects will take cabozantinib orally, once per day, in cycles of 28 days. During each cycle subjects will have the following procedures: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug * Urine sample for routine urine tests to monitor health On Day 15 (beginning of week 3) during the first 3 cycles: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug Subjects will receive a CT scan or MRI every two cycles (every two months) to evaluate disease.